Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 over exp |
| Therapy | Cemiplimab |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 over exp | lung adenocarcinoma | sensitive | Cemiplimab | Guideline | Actionable | Libtayo (cemiplimab) is included in guidelines as preferred first-line therapy (category 1) for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of at least 50% and negative for actionable molecular biomarkers, and negative for actionable molecular biomarkers (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |